The FDA has approved a nasal spray to treat major depressive disorder, which gives those suffering from treatment-resistant depression a new option.

22% of those who tested the Spravato nasal spray, which is made from the drug esketamine, reported improvements in mood in a study.

The manufacturer, Johnson & Johnson, claims patients can see mood improvement in as little as 24 hours.

There is a risk of abusing the nasal spray, though, so it will be prescribed under restricted programs through certified treatment centers.

A Gallup poll found that 23% of American adults have been diagnosed with depression.

https://www.newsweek.com/fda-depression-treatment-nasal-spray-2018722